37 results about "Neuronal disease" patented technology

A combined neuromodulation and / or neurostimulation system for mitigating locomotor deficits of / or neuronal disorders, especially Parkinson's disease, said system comprises: at least one Deep Brain Stimulation System for providing Deep Brain Stimulation to brain tissue of a subject, at least one control unit, configured and adapted to provide stimulation data, at least one stimulation unit, operatively connected to the at least one control unit, the at least one stimulation unit being configured and adapted to deliver epidural electrical stimulation to the dorsal side of the spinal cord of said subject, and at least one implantable pulse generator, wherein the at least one stimulation unit includes one or more electrodes configured to be implanted epidurally, the one or more electrodes being operatively connected to the at least one IPG.

The present invention refers to a method for producing a polymer in form of a gel or a particle, and to the resulting polymer, gel and particle, respectively. The polymer comprises a carbon donor and a metal oxide precursor, a metal oxide or a combination thereof and optionally an active agent. The invention is further directed to a composition and film comprising such polymer, and their use as a medicament for example in treating diabetes, obesity, neuronal disease, viral infection or cancer.

The present invention relates to salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine and pharma-ceutically acceptable solvates thereof for use in the treatment and / or prevention of sensory neuron diseases.

The present invention relates to sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine and pharmaceutically acceptable solvates thereof, for use in the treatment and / or prevention of motor neuron diseases and neuromuscular junction disorders.

Disclosed herein are embodiments of a compound that inhibits c-Abl tyrosine kinase (also referred to herein as “c-Abl”). The compound embodiments described herein are novel c-Abl inhibitors that can bind to c-Abl at an allosteric site and inhibit its activity in various pathways. The compound embodiments also are capable of crossing the blood brain barrier and therefore are useful in inhibiting c-Abl activity as it affects pathways and / or proteins in the brain. The compound embodiments described herein are effective therapeutic agents for treating diseases involving c-Abl, such as cancers, motor neuron diseases, and neurodegenerative diseases. Also disclosed herein are embodiments of methods for making and using the c-Abl inhibitory compound embodiments.

Disclosed are compositions and / or methods of use of the compositions for patients with neuronal diseases such as AD, Parkinson's, Huntington's, multiple sclerosis, and ALS. In certain embodiments flavonoids alone, or in a pharmaceutical preparation, are administered through the nasal olfactory route. In certain embodiments the flavonoid is apigenin and the neural disease is Alzheimer's. In some embodiments a porosome complex is administered for reconstitution into a neural cell. In certain embodiments, a co-administered blood-brain barrier traversing peptide is configured as a mimic of a domain of ATP 1 A3 and / or Tubulin.

Antibodies that specifically bind to TrkB and methods for using the same are described. Neuroprotective agonist antibodies are described, as indicated by their effect on enhancing the survival of retinal ganglion cells in vitro, and these agonist antibodies may be used to treat eye disorders, such as glaucoma. Additionally, other neuronal diseases or disorders, including those characterized by partial neuronal damage, benefit from treatment using these agonist antibodies. In certain embodiments, the present invention comprises antibodies that bind to TrkB and mediate cell signaling. The antibodies of the present invention may be whole human, non-natural antibodies formulated as injectable excipients.

As a result of performing an analysis exclusively on lower limb type and upper limb type ALS, excluding the bulbar palsy type ALS, among ALS for which it had been considered in existing reports that a reduction in Crtac1B was not observed, a significant correlation between the prognosis and the Crtac1B concentration in the cerebrospinal fluid was observed. Thus, it was discovered that Crtac1B is useful as a biomarker for predicting the prognosis of lower limb type and upper limb type ALS. As a result of analyzing the association between the motor function and the Crtac1B concentration in the cerebrospinal fluid before and after treatment in SMA patients treated with an SMA therapeutic agent, it was found that the Crtac1B concentration in the cerebrospinal fluid reflects the disease progression of SMA, and that Crtac1B is useful as a biomarker for diagnosing the therapeutic effect by the SMA therapeutic agent.

Antibodies that specifically bind to TrkB and methods of use thereof are disclosed. Agonist antibodies having neuroprotective effects, as shown by their ability to enhance retinal ganglion cell survival in vitro, are disclosed, and these agonist antibodies can be used in the treatment of conditions such as eye diseases, including glaucoma. In addition, other neuronal diseases or conditions can also benefit from treatment with these agonist antibodies, including those characterized in part by neuronal damage. In certain embodiments, the present invention includes antibodies that bind to TrkB and mediate cell signaling. The antibodies of the present invention can be fully human, non-naturally occurring antibodies formulated with an excipient for injection.

A method for treating a patient suffering from a neuronal hypo-kinetic disease or a neuronal hyper-kinetic disease by modulating neuronal activity in the: internal globus pallidus (GPi), in the anterior motor thalamus and / or in the external globus pallidum (GPe) and / or in the subthalamic nucleus (STN) by utilizing suppressor and / or enhancer DREADDs is provided.

Presented herein are methods of identifying a subject who has, or is at risk of developing a motor neuron disease, specifically Amyotrophic Lateral Sclerosis (ALS), and / or Primary Lateral Sclerosis (PLS), that includes determining a presence or amount of two or more micro-RNAs (miRNAs) selected from miR-199a-3p, miR-4454, miR-10b-5p, miR-151a-5p, miR-199a-5p, miR-151a-3p, miR-146a-5p, and / or miR-29b-3p in a subject's circulating blood, without determining a presence or amount of the miRNAs from neural-derived exosomes. Also presented herein are methods of preventing, treating, or delaying the onset of a motor neuron disease, specifically ALS and / or PLS.

The present invention relates to multifunctional agents as defined in the claims based on N-substituted 1,4-benzothiazepines with cyclopropanol groups and their "open" analogues (such as the 3-[(4-methoxyphenyl)oxy]- and 3-[(4-methoxyphenyl)thio]propane-1-amine cyclopropanol derivatives; see formulae below) as well as the rearrangement products obtained from such cyclopropanol compounds, i.e. ethyl ketones, and the oxidation products from such cyclopropanol compounds, i.e. oxiranes. Such compounds can be used by preventing Ca2+ leak through ryanodine receptor 2 (RyR2) and enhance cardiac sarco-endoplasmic reticulum (SR) Ca2+ load by activation of Ca2+-dependent ATPase 2a (SERCA2a) for example for the treatment of cardiac or neuronal diseases.

The invention relates inter alia to a protein which is a VTFT isoform of a BPIFB4 protein or a functional fragment thereof for use in the treatment or prophylaxis of a condition selected from neuronal diseases and injuries, said diseases and injuries being associated with mitochondrial dysfunction and / or protein aggregation and / or ameliorated by CXCR4 activation.

The present invention relates to a method for identifying and detecting the expression of biomarkers present in choroidal and retinal pigmented epithelium disorders or in ocular angiogenic, epithelial and neuronal disorders. The invention further encompasses a kit for biomarker identification and uses thereof. The present invention pertains to the field of chemical biology, more specifically in the healthcare sector, and describes a method for identifying and detecting the expression of a set of biomarkers present in severe ophthalmological diseases.

Aspects of the present disclosure relate to methods and compositions relating to the selection and expansion of immune cells, including T cells expressing CD16Hi in combination with a V [delta] 2 T cell receptor. The T cells generated by the methods disclosed herein are suitable for allogeneic cell therapy as they do not induce graft versus host disease (GvHD) and resist host immune allogeneic rejection. Thus, such cells are suitable for ready-to-use in clinical therapy for diseases such as cancer, infectious diseases, autoimmune diseases, heart diseases and neuronal diseases.

Disclosed herein are compound embodiments that are useful for treating a variety of diseases, particularly neurological diseases, motor neuron diseases, copper deficiency-related diseases, and / or mitochondrial deficiencies. The compound embodiments described herein also can be used in PET methods. Also disclosed herein are embodiments of methods of making and using the compound embodiments, as well as pharmaceutical formulations comprising the disclosed compound embodiments.

Disclosed are compositions and / or methods of use of the compositions for patients with neuronal diseases such as AD, Parkinson's, Huntington's, multiple sclerosis, and ALS. In certain embodiments flavonoids alone, or in a pharmaceutical preparation, are administered through the nasal olfactory route. In certain embodiments the flavonoid is apigenin and the neural disease is Alzheimer's. In some embodiments a porosome complex is administered for reconstitution into a neural cell. In certain embodiments, a co-administered blood-brain barrier traversing peptide is configured as a mimic of a domain of ATP1A3 and / or Tubulin.

Provided herein are methods and compositions related to treating motor neuron diseases, such as ALS, in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide riboside, pterostilbene and a phosphodiesterase (PDE) inhibitor, including a PDE4 inhibitor such as ibudilast, and also including a thiol / cysteine donor, such as acetylcysteine.

Disclosed are compositions and / or methods of use of the compositions for patients with neuronal diseases such as AD, Parkinson's, Huntington's, multiple sclerosis, and ALS. In certain embodiments flavonoids alone, or in a pharmaceutical preparation, are administered through the nasal olfactory route. In certain embodiments the flavonoid is apigenin and the neural disease is Alzheimer's. Targeted dosages may affect mitochondrial function in brain neural cells thus ameliorating a neural disease. In some embodiments a porosome complex is administered for reconstitution into a neural cell. In certain embodiments, one or more macrocyclic or linear peptides are administered.

Presented herein are methods of identifying a subject who has, or is at risk of developing a motor neuron disease, specifically Amyotrophic Lateral Sclerosis (ALS), and / or Primary Lateral Sclerosis (PLS), that includes determining a presence or amount of two or more micro-RNAs (miRNAs) selected from miR-199a-3p, miR-4454, miR-10b-5p, miR-151a-5p, miR-199a-5p, miR-151a-3p, miR-146a-5p, and / or miR-29b-3p in a subject's circulating blood, without determining a presence or amount of the miRNAs from neural-derived exosomes. Also presented herein are methods of preventing, treating, or delaying the onset of a motor neuron disease, specifically ALS and / or PLS.

The instant invention provides methods and compositions related to discovery of Free Fatty Acid Receptor 1 (FFA1) as a therapeutic target for treatment or prevention of diseases or disorders of neurons that are characterized by angiogenesis, or of vascular diseases of the eye, retinal degeneration and / or tumors more generally. Therapeutic and / or prophylactic uses and compositions of known FFA1 inhibitors, including small molecules and nucleic acid agents, are described. Methods for identification of novel FFA1 inhibitors are also provided.

Disclosed are compositions and / or methods of use of the compositions for patients with neuronal diseases such as AD, Parkinson's, Huntington's, multiple sclerosis, and ALS. In certain embodiments flavonoids alone, or in a pharmaceutical preparation, are administered through the nasal olfactory route. In certain embodiments the flavonoid is apigenin and the neural disease is Alzheimer's. Targeted dosages may affect mitochondrial function in brain neural cells thus ameliorating a neural disease. In some embodiments a porosome complex is administered for reconstitution into a neural cell. In certain embodiments, one or more macrocyclic or linear peptides are administered.

Disclosed herein are methods for treating a motor neuron disease such as amyotrophic lateral sclerosis (ALS) comprising administering mEphA4-Fc with an interval of greater than every week, for example administering mEphA4-Fc every two weeks, every three weeks, or every four weeks, and at a concentration of about 10 to about 40 mg / kg body weight of a subject.

Disclosed herein are stable peptide antagonists based on the consensus yc-subunit binding site to inhibit the activity of yc-cytokines. Such peptide antagonists are capable of inhibiting the activity of multiple yc-cytokine family members. The yc-family cytokines are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of yc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools.

The present application relates to pyrimidopyridone and pteridinone compounds of formula I, processes for their preparation and compositions comprising them. More particularly, the present application relates to compounds of formula I having activity as inhibitors of GCN2 kinase and their use in the treatment of diseases, disorders or conditions treatable by inhibition of GCN2 kinase, such as cancer and neuronal diseases. (I).

Disclosed herein are embodiments of a compound that inhibits c-Abl tyrosine kinase (also referred to herein as “c-Abl”). The compound embodiments described herein are novel c-Abl inhibitors that can bind to c-Abl at an allosteric site and inhibit its activity in various pathways. The compound embodiments also are capable of crossing the blood brain barrier and therefore are useful in inhibiting c-Abl activity as it affects pathways and / or proteins in the brain. The compound embodiments described herein are effective therapeutic agents for treating diseases involving c-Abl, such as cancers, motor neuron diseases, and neurodegenerative diseases. Also disclosed herein are embodiments of methods for making and using the c-Abl inhibitory compound embodiments.

Inhibitors of C / EBP homologous protein (CHOP) are provided. The inhibitors find use in the modulation of endoplasmic reticulum (ER) stress, and the treatment of conditions involving ER stress, including neuronal conditions.

Disclosed is a producing method of a mesenchymal stem cell for brain neuronal disease prevention or treatment including ghrelin treatment, a composition for producing a mesenchymal stem cell for brain neuronal disease prevention or treatment, a mesenchymal stem cell produced by the producing method, and a pharmaceutical composition for prevention or treatment of brain neuronal disease containing the same. When using the producing method of the mesenchymal stem cells with the increased AgRP (Agouti related peptide) expression level according to the present disclosure, the mesenchymal stem cells produced by the method, or ghrelin, various brain neuronal diseases such as Alzheimer's disease may be effectively prevented or treated. When the composition for producing the mesenchymal stem cells with the increased AgRP expression level containing ghrelin according to the present disclosure is used, the mesenchymal stem cells with the increased AgRP expression level may be effectively produced.

The present invention provides a compound having a cell degeneration inhibitory action, particularly a motor neuron degeneration inhibitory action, which is useful as an agent for the prophylaxis or treatment of motor neuron diseases (e.g., amyotrophic lateral sclerosis, progressive bulbar paralysis, progressive muscular atrophy, primary lateral sclerosis, progressive pseudobulbar paralysis, spinal muscular atrophy, Parkinson's disease, Lewy body dementia, multiple-system atrophy, Friedreich's ataxia) and the like.The present invention relates to a compound represented by the formula (I):wherein each symbol is as described in the specification, or a salt thereof.